zintick

Replimune Group REPL

Replimune Group, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$16.06+23.07%close on Oct. 28, 2026 · volume 7.3M · Yahoo Finance

Price, last 47 sessions

$12.00$14.00$16.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $16.06 · low $10.86 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Aug. 17, 2026Emily Luisa Hill
Chief Financial Officer
Sold9,256$14.28$132,176
Aug. 10, 2026Sushil Patel
Chief Executive Officer, director
Sold39,341$12.97$510,253
Aug. 10, 2026Emily Luisa Hill
Chief Financial Officer
Sold11,448$12.97$148,481
Aug. 10, 2026Konstantinos Xynos
Chief Medical Officer
Sold11,447$12.97$148,468
Aug. 10, 2026Andrew Schwendenman
Chief Accounting Officer
Sold7,632$12.97$98,987

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 23 →
  • 10-QOct. 28, 2026, 7:25 a.m. ETView on SEC.gov
  • 8-KOct. 28, 2026, 7:05 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedReplimune Reports Fiscal Q2 2027 Net Loss of $0.54 per Share, Narrower Than $0.79 Consensus, as TUDRIQEV Launches

  • 8-KSept. 16, 2026, 4:05 p.m. ETView on SEC.gov

    Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Financial statements and exhibits

  • 4Aug. 24, 2026, 7:48 p.m. ETView on SEC.gov
  • 4Aug. 19, 2026, 6:42 p.m. ETView on SEC.gov
  • 10-QAug. 14, 2026, 4:07 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 4 p.m. ETView on SEC.gov
  • 8-KAug. 14, 2026, 8:10 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits